Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07314073 | [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer | recruiting | Phase 2 | 85 | Asan Medical CenterOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07037199 | Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer | recruiting | Phase 2 | 45 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06452394 | NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline | recruiting | Phase 2 | 50 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06596018 | Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy | recruiting | Phase 1 / Phase 2 | 96 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07307287 | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07305246 | Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer | not yet recruiting | Phase 2 | 120 | First Hospital of China Medical UniversityOTHER | 0 | Dec 26, 2025 | clinicaltrials |
| NCT04965766 | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer(ICARUS BREAST) | recruiting | Phase 2 | 139 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299409 | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | not yet recruiting | Phase 2 | 24 | Nathalie LevasseurOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299890 | An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | not yet recruiting | Phase 2 | 90 | Anhui Provincial Cancer HospitalOTHER | 0 | Dec 23, 2025 | clinicaltrials |
| NCT07300215 | An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Dec 23, 2025 | clinicaltrials |
| NCT03285412 | CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer(LEADER) | active not recruiting | Phase 2 | 120 | Massachusetts General HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06085742 | BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer(BRE-08) | recruiting | Phase 2 | 25 | University of Illinois at ChicagoOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06498154 | Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy | recruiting | Phase 2 | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07290166 | A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.(Cinderella-Neo) | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 0 | Dec 18, 2025 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07292207 | Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer(ARCHE) | not yet recruiting | Phase 2 | 30 | Nagoya City UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04563507 | Combined Immunotherapies in Metastatic ER+ Breast Cancer | recruiting | Phase 2 | 102 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04965064 | Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling | recruiting | Phase 2 | 22 | University of RochesterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06107673 | Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | recruiting | Phase 2 | 144 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06961955 | 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer(FAST NOVEMBER) | recruiting | Phase 2 | 144 | University of UtahOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT06910761 | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06731894 | Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | recruiting | Phase 2 | 120 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06817525 | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC | recruiting | Phase 2 | 64 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06409390 | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | recruiting | Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05076682 | Reverse Triple Negative Immune Resistant Breast Cancer(Renaissance) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06735131 | The Optimal Radioimmunotherapy Combinations for Advanced TNBC | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06189209 | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07159451 | A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer(POP-ELA) | recruiting | Phase 2 | 140 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07255612 | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | enrolling by invitation | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | not yet recruiting | Phase 2 | 188 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05982678 | Basket Study for Oligo-metastatic Breast Cancer(ANISE) | recruiting | Phase 2 | 72 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07245069 | Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients(Alpaca) | recruiting | Phase 2 | 100 | University Medical Centre LjubljanaOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06185205 | ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy(ASHBY) | recruiting | Phase 2 | 170 | Virginia Commonwealth UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2026source: clinicaltrials